EUVIMEDEUVIMED entdecken
Crossref

3‐[[4‐(Benzylamino)quinazolin‐2‐yl] Amino] Benzenesulfonamide, a Quinazoline‐Based PDE5 Inhibitor, Induces Vasorelaxation in Rat Mesenteric Arteries via Multiple Mechanisms

Usana Chatturong, Krongkarn Chootip iD, M Paul Gleeson iD, Guntur Guntur iD, Yasuteru Shigeta iD, Kowit Hengphasatporn iD, Perle Totoson, Céline Demougeot

Basic & Clinical Pharmacology & Toxicology · 2026

DOI: 10.1111/bcpt.70324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Usana Chatturong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medical Science and Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok, Thailand. Hauptthemen laut MEDLINE: Mesenteric Arteries, Vasodilation, Vasodilator Agents, Sulfonamides. Die Arbeit nennt 53 Literaturangaben. Gefördert von: National Research Council of Thailand, Naresuan University (NU), National Science, Research and Innovation Fund (NSRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We synthesised a series of N 2 , N 4 ‐diaminoquinazoline derivatives, among which 3‐[[4‐(benzylamino)quinazolin‐2‐yl]amino]benzenesulfonamide (compound 5 ) exhibited potent phosphodiesterase type 5 (PDE5) inhibitory activity. Increasing evidence suggests that PDE5 inhibition is a promising therapeutic strategy for peripheral vascular disease. This study aimed to investigate vasorelaxant effects of 5 and its underlying mechanisms in rat mesenteric arteries. Compound 5 was synthesised and purified, and evaluated its vascular activity using organ bath assay. Molecular docking was performed to identify its potential molecular targets. Compound 5 (0.0001–30 μM) induced relaxation of phenylephrine (PE)‐precontracted mesenteric arteries (EC 50 = 0.76 ± 0.29 μM; E max = 95.6% ± 1.1%). This effect was attenuated by endothelium removal (EC 50 = 5.24 ± 0.98 μM) and by L‐NAME (eNOS inhibitor). Compound 5 enhanced sodium nitroprusside–induced relaxation, supporting modulation of the NO–sGC–cGMP axis via PDE5 inhibition. Iberiotoxin (BK Ca blocker) reduced relaxation, whereas 4‐aminopyridine (K V blocker) and glibenclamide (K ATP blocker) had no effect. Compound 5 inhibited vasoconstriction mediated by extracellular Ca 2+ influx via receptor‐operated Ca 2+ channels (ROCCs) and α 1 ‐adrenergic receptor activation. Molecular docking provided qualitative support for PDE5A, BK Ca channels and α 1 ‐adrenergic receptor as potential targets. In conclusion, 5 induces potent vasorelaxation in resistance arteries through eNOS/NO/cGMP signalling, BK Ca channel activation and inhibition of ROCCs and α 1 ‐adrenergic receptors, supporting its potential as a therapeutic candidate for peripheral vascular disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenteric ArteriesVasodilationVasodilator AgentsSulfonamidesPhosphodiesterase 5 InhibitorsQuinazolinesAnimalsRatsMolecular Docking SimulationMaleBenzenesulfonamidesRats, Sprague-DawleyCyclic Nucleotide Phosphodiesterases, Type 5Endothelium, VascularNitric OxideCyclic GMP

Stichwörter der Autor:innen

PDE5A inhibitorcGMPcalcium channelmesenteric arterynitric oxidepotassium channelvasorelaxation

Substanzen

Vasodilator AgentsSulfonamidesBenzenesulfonamidesPhosphodiesterase 5 InhibitorsQuinazolinesCyclic Nucleotide Phosphodiesterases, Type 5Nitric OxideCyclic GMP

Autor:innen und Institutionen

  • Department of Physiology, Faculty of Medical Science and Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok, Thailand.
  • Department of Biomedical Engineering, Faculty of Engineering, King Mongkut's Institute of Technology, Ladkrabang, Bangkok, Thailand.
  • Center for Computational Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Marie and Louis Pasteur University, EFS, INSERM, RIGHT (UMR1098), Besançon, France.

ORCID-Profile: Krongkarn Chootip, M Paul Gleeson, Guntur Guntur, Yasuteru Shigeta, Kowit Hengphasatporn

Förderung

  • National Research Council of Thailand
  • Naresuan University (NU)
  • National Science, Research and Innovation Fund (NSRF)
  • Royal Golden Jubilee
  • Franco-Thai Scholarship Program
  • French Ministry for Higher Education and Research
  • Global and Frontier Research University Fund, Naresuan University
  • JSPS KAKENHI

Zitieren

APA

Chatturong, U., Chootip, K., Gleeson, M. P., Guntur, G., Shigeta, Y., Hengphasatporn, K., Totoson, P., & Demougeot, C. (2026). 3‐[[4‐(Benzylamino)quinazolin‐2‐yl] Amino] Benzenesulfonamide, a Quinazoline‐Based PDE5 Inhibitor, Induces Vasorelaxation in Rat Mesenteric Arteries via Multiple Mechanisms. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70324

Vancouver

Chatturong U, Chootip K, Gleeson MP, Guntur G, Shigeta Y, Hengphasatporn K, et al. 3‐[[4‐(Benzylamino)quinazolin‐2‐yl] Amino] Benzenesulfonamide, a Quinazoline‐Based PDE5 Inhibitor, Induces Vasorelaxation in Rat Mesenteric Arteries via Multiple Mechanisms. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70324

BibTeX
@article{Chatturong2026,
  author = {Chatturong, Usana and Chootip, Krongkarn and Gleeson, M Paul and Guntur, Guntur and Shigeta, Yasuteru and Hengphasatporn, Kowit and Totoson, Perle and Demougeot, Céline},
  title = {3‐[[4‐(Benzylamino)quinazolin‐2‐yl] Amino] Benzenesulfonamide, a Quinazoline‐Based PDE5 Inhibitor, Induces Vasorelaxation in Rat Mesenteric Arteries via Multiple Mechanisms},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  doi = {10.1111/bcpt.70324}
}
Kostenlos starten →